Bluetongue in endemic or high risk areas
Article 4
1. The programmes for the eradication and monitoring of bluetongue submitted by Belgium, Bulgaria, the Czech Republic, Denmark, Germany, Estonia, Ireland, Greece, Spain, France, Italy, Latvia, Lithuania, Luxembourg, Hungary, Malta, the Netherlands, Austria, Poland, Portugal, Romania, Slovenia, Finland and Sweden are hereby approved for the period from 1 January 2009 to 31 December 2009. 2. The financial contribution by the Community shall be at the rate of 50 % of the costs to be incurred by each Member State referred to in paragraph 1 for the cost of carrying out the laboratory tests for virological, serological and entomological surveillance and the purchase of traps and vaccines, and shall not exceed: (a) EUR 1 200 000 for Belgium; (b) EUR 5 000 for Bulgaria; (c) EUR 790 000 for the Czech Republic; (d) EUR 840 000 for Denmark; (e) EUR 4 100 000 for Germany; (f) EUR 10 000 for Estonia; (g) EUR 1 000 000 for Ireland; (h) EUR 50 000 for Greece; (i) EUR 16 100 000 for Spain; (j) EUR 19 100 000 for France; (k) EUR 9 000 000 for Italy; (l) EUR 70 000 for Latvia; (m) EUR 50 000 for Lithuania; (n) EUR 220 000 for Luxembourg; (o) EUR 500 000 for Hungary; (p) EUR 5 000 for Malta; (q) EUR 2 100 000 for the Netherlands; (r) EUR 1 500 000 for Austria; (s) EUR 500 000 for Poland; (t) EUR 3 200 000 for Portugal; (u) EUR 250 000 for Romania; (v) EUR 250 000 for Slovenia; (w) EUR 50 000 for Finland; (x) EUR 370 000 for Sweden. 3. The maximum of the costs to be reimbursed to the Member States for the programmes referred to in paragraph 1 shall on average not exceed: (a) for an ELISA test EUR 2,5 per test; (b) for a PCR test EUR 10 per test; (c) For vaccine purchase EUR 0,3 per dose.